Cells from primary effusion lymphoma (PEL), a non-Hodgkin’s B-cell lymphoma, were treated with arctigenin which markedly inhibited the proliferation of PEL by decreasing cellular ATP levels, disrupting mitochondrial membrane potential and triggering caspase-9-mediated apoptosis. This evidence concerns the gene CASP9 and primary effusion lymphoma.